Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of a Dengue Tetravalent Vaccine (TDV) in Adults and Older Adults
NCT06579755Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Jan 2026
- Primary completion
- Apr 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 4
01
Overview
A Phase 3 trial of live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus in dengue fever, sponsored by Takeda. Started Jan 2026; status: active, not recruiting.
02
Drugs
live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT06579755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06579755.